{"id":61249,"date":"2026-03-25T14:43:54","date_gmt":"2026-03-25T06:43:54","guid":{"rendered":"https:\/\/flcube.com\/?p=61249"},"modified":"2026-03-25T14:43:54","modified_gmt":"2026-03-25T06:43:54","slug":"atom-therapeutics-files-hong-kong-ipo-urat1-inhibitor-abp-671-targets-first-line-gout-treatment-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61249","title":{"rendered":"Atom Therapeutics Files Hong Kong IPO \u2013 URAT1 Inhibitor ABP-671 Targets First\u2011Line Gout Treatment Market"},"content":{"rendered":"\n<p><strong>Atom Therapeutics Co., Ltd.<\/strong> has <strong>submitted an initial public offering (IPO) filing<\/strong> to the <strong>Hong Kong Stock Exchange<\/strong>, seeking capital markets access to advance its <strong>metabolism, inflammation, and cardiovascular disease pipeline<\/strong> \u2013 anchored by <strong>ABP-671<\/strong>, a <strong>first\u2011in\u2011class URAT1 inhibitor<\/strong> positioned for <strong>first\u2011line gout treatment<\/strong> with <strong>Phase IIb\/III trials underway in China and the United States<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ipo-overview\">IPO Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Atom Therapeutics Co., Ltd.<\/td><\/tr><tr><td><strong>Founded<\/strong><\/td><td>2012<\/td><\/tr><tr><td><strong>Exchange<\/strong><\/td><td>Hong Kong Stock Exchange<\/td><\/tr><tr><td><strong>Filing<\/strong><\/td><td>IPO prospectus submitted<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Metabolism, inflammation, cardiovascular diseases<\/td><\/tr><tr><td><strong>Lead Asset<\/strong><\/td><td>ABP-671 \u2013 URAT1 inhibitor for gout<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-portfolio\">Pipeline Portfolio<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Stage<\/th><th>Indication\/Class<\/th><th>Strategic Positioning<\/th><\/tr><\/thead><tbody><tr><td><strong>ABP-671<\/strong><\/td><td><strong>Phase IIb\/III<\/strong><\/td><td><strong>URAT1 inhibitor \u2013 first\u2011line gout<\/strong><\/td><td>Core product; China + US development<\/td><\/tr><tr><td><strong>ABP-745<\/strong><\/td><td>Clinical\u2011stage<\/td><td>Metabolism\/inflammation<\/td><td>Pipeline diversification<\/td><\/tr><tr><td><strong>AT6616<\/strong><\/td><td>Preclinical<\/td><td>Metabolism\/cardiovascular<\/td><td>Early\u2011stage optionality<\/td><\/tr><tr><td><strong>ABP-6016<\/strong><\/td><td>Preclinical<\/td><td>Inflammation<\/td><td>Platform expansion<\/td><\/tr><tr><td><strong>ABP-6118<\/strong><\/td><td>Preclinical<\/td><td>Cardiovascular<\/td><td>Long\u2011term growth driver<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-lead-asset-abp-671-profile\">Lead Asset \u2013 ABP-671 Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Specification<\/th><th>Competitive Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Mechanism<\/strong><\/td><td><strong>URAT1 (urate transporter 1) inhibitor<\/strong><\/td><td>Blocks renal uric acid reabsorption<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td><strong>First\u2011line gout treatment<\/strong><\/td><td>Addresses root cause (hyperuricemia) vs. symptom management<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Phase IIb\/III (China + US)<\/td><td>Global regulatory strategy; de\u2011risked by Phase II data<\/td><\/tr><tr><td><strong>Origin<\/strong><\/td><td><strong>In\u2011house developed<\/strong> \u2013 small molecule<\/td><td>Full IP control; manufacturing cost advantages<\/td><\/tr><tr><td><strong>Differentiation<\/strong><\/td><td><strong>Superior uric acid\u2011lowering efficacy + safety<\/strong> vs. existing first\u2011line therapies (allopurinol, febuxostat) and major investigational drugs<\/td><td>Best\u2011in\u2011class potential; addresses febuxostat cardiovascular safety concerns<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-strategic-positioning\">Market Context &amp; Strategic Positioning<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>Gout Treatment Landscape<\/th><th>ABP-671 Position<\/th><\/tr><\/thead><tbody><tr><td><strong>Market Size<\/strong><\/td><td>Global <strong>US$3\u20114 billion<\/strong>; China <strong>RMB8\u201112 billion<\/strong> annually<\/td><td>Large addressable market with unmet need for safer first\u2011line options<\/td><\/tr><tr><td><strong>Standard of Care<\/strong><\/td><td>Allopurinol (first\u2011line, generic, suboptimal efficacy in rapid metabolizers); febuxostat (second\u2011line, cardiovascular safety concerns)<\/td><td><strong>Next\u2011generation URAT1 inhibitor<\/strong> \u2013 improved efficacy + safety profile<\/td><\/tr><tr><td><strong>Unmet Need<\/strong><\/td><td>~40\u201150% of patients fail to reach target serum uric acid (&lt;6 mg\/dL) with allopurinol; febuxostat boxed warning (cardiovascular mortality)<\/td><td><strong>First\u2011line positioning<\/strong> with superior efficacy and <strong>cardiovascular safety<\/strong><\/td><\/tr><tr><td><strong>Competitive Pipeline<\/strong><\/td><td>Dotinurad (Japan); lesinurad (withdrawn); verinurad (Phase II)<\/td><td>ABP-671 <strong>Phase IIb\/III advancement<\/strong> positions for <strong>first\u2011to\u2011market<\/strong> among next\u2011gen URAT1 inhibitors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-ipo-considerations\">Market Impact &amp; IPO Considerations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Hong Kong Biotech IPO Window:<\/strong> 2025\u20112026 HKEX listings demonstrate <strong>investor appetite<\/strong> for clinical\u2011stage metabolism assets; Atom&#8217;s <strong>first\u2011line gout positioning<\/strong> addresses <strong>large chronic disease market<\/strong> with clear unmet need; estimated <strong>US$150\u2011300 million<\/strong> fundraising target assuming 15\u201120% post\u2011IPO float.<\/li>\n\n\n\n<li><strong>ABP-671 Clinical Validation:<\/strong> Phase IIb\/III design (vs. allopurinol non\u2011inferiority\/superiority) supports <strong>2027\u20112028 NDA submissions<\/strong> China and US; <strong>cardiovascular safety database<\/strong> critical for differentiation vs. febuxostat; <strong>combination potential<\/strong> with lesinurad\u2011like URAT1\/xanthine oxidase dual therapy.<\/li>\n\n\n\n<li><strong>Global Expansion Strategy:<\/strong> <strong>US Phase IIb\/III<\/strong> validates <strong>FDA regulatory pathway<\/strong>; <strong>China\u2011first approval<\/strong> (2028\u20112029) enables <strong>domestic revenue generation<\/strong> before US launch; <strong>ex\u2011China partnership<\/strong> (Europe, Japan) likely upon Phase III interim data; estimated <strong>US$300\u2011500 million<\/strong> upfront for EU\/Japan rights.<\/li>\n\n\n\n<li><strong>Pipeline Optionality:<\/strong> ABP\u2011745 clinical\u2011stage asset provides <strong>downside protection<\/strong> if ABP\u2011671 encounters setbacks; preclinical portfolio (AT6616, ABP\u20116016, ABP\u20116118) demonstrates <strong>platform\u2011based discovery capabilities<\/strong>; potential for <strong>indication expansion<\/strong> (chronic kidney disease with hyperuricemia, tumor lysis syndrome prophylaxis).<\/li>\n\n\n\n<li><strong>Risk Factors:<\/strong> <strong>Crowded gout market<\/strong> with generic allopurinol dominance; <strong>NRDL pricing pressure<\/strong> in China (likely RMB5,000\u20118,000 annually vs. originator febuxostat RMB10,000+); <strong>cardiovascular outcome trial requirements<\/strong> for US FDA approval; <strong>competitive urgency<\/strong> (Innovent&#8217;s tigulizostat, Hengrui&#8217;s uric acid\u2011lowering assets in development).<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding IPO completion timelines, clinical development milestones, and commercial expectations for ABP\u2011671. Actual results may differ due to market volatility, competitive dynamics in the gout therapeutics market, and regulatory requirements for cardiovascular safety demonstration.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/sehk26032001842_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk26032001842_c.\"><\/object><a id=\"wp-block-file--media-b8e9962a-26b0-4d79-9b1e-c0149176044f\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/sehk26032001842_c.pdf\">sehk26032001842_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/sehk26032001842_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-b8e9962a-26b0-4d79-9b1e-c0149176044f\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Atom Therapeutics Co., Ltd. has submitted an initial public offering (IPO) filing to the Hong&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[2578,72],"class_list":["post-61249","post","type-post","status-publish","format-standard","hentry","category-company","tag-atom-therapeutics","tag-ipo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Atom Therapeutics Files Hong Kong IPO \u2013 URAT1 Inhibitor ABP-671 Targets First\u2011Line Gout Treatment Market - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Atom Therapeutics Co., Ltd. has submitted an initial public offering (IPO) filing to the Hong Kong Stock Exchange, seeking capital markets access to advance its metabolism, inflammation, and cardiovascular disease pipeline \u2013 anchored by ABP-671, a first\u2011in\u2011class URAT1 inhibitor positioned for first\u2011line gout treatment with Phase IIb\/III trials underway in China and the United States.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=61249\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Atom Therapeutics Files Hong Kong IPO \u2013 URAT1 Inhibitor ABP-671 Targets First\u2011Line Gout Treatment Market\" \/>\n<meta property=\"og:description\" content=\"Atom Therapeutics Co., Ltd. has submitted an initial public offering (IPO) filing to the Hong Kong Stock Exchange, seeking capital markets access to advance its metabolism, inflammation, and cardiovascular disease pipeline \u2013 anchored by ABP-671, a first\u2011in\u2011class URAT1 inhibitor positioned for first\u2011line gout treatment with Phase IIb\/III trials underway in China and the United States.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=61249\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-25T06:43:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61249#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61249\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Atom Therapeutics Files Hong Kong IPO \u2013 URAT1 Inhibitor ABP-671 Targets First\u2011Line Gout Treatment Market\",\"datePublished\":\"2026-03-25T06:43:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61249\"},\"wordCount\":597,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Atom Therapeutics\",\"IPO\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61249#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61249\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=61249\",\"name\":\"Atom Therapeutics Files Hong Kong IPO \u2013 URAT1 Inhibitor ABP-671 Targets First\u2011Line Gout Treatment Market - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-25T06:43:54+00:00\",\"description\":\"Atom Therapeutics Co., Ltd. has submitted an initial public offering (IPO) filing to the Hong Kong Stock Exchange, seeking capital markets access to advance its metabolism, inflammation, and cardiovascular disease pipeline \u2013 anchored by ABP-671, a first\u2011in\u2011class URAT1 inhibitor positioned for first\u2011line gout treatment with Phase IIb\\\/III trials underway in China and the United States.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61249#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61249\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61249#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Atom Therapeutics Files Hong Kong IPO \u2013 URAT1 Inhibitor ABP-671 Targets First\u2011Line Gout Treatment Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Atom Therapeutics Files Hong Kong IPO \u2013 URAT1 Inhibitor ABP-671 Targets First\u2011Line Gout Treatment Market - Insight, China&#039;s Pharmaceutical Industry","description":"Atom Therapeutics Co., Ltd. has submitted an initial public offering (IPO) filing to the Hong Kong Stock Exchange, seeking capital markets access to advance its metabolism, inflammation, and cardiovascular disease pipeline \u2013 anchored by ABP-671, a first\u2011in\u2011class URAT1 inhibitor positioned for first\u2011line gout treatment with Phase IIb\/III trials underway in China and the United States.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=61249","og_locale":"en_US","og_type":"article","og_title":"Atom Therapeutics Files Hong Kong IPO \u2013 URAT1 Inhibitor ABP-671 Targets First\u2011Line Gout Treatment Market","og_description":"Atom Therapeutics Co., Ltd. has submitted an initial public offering (IPO) filing to the Hong Kong Stock Exchange, seeking capital markets access to advance its metabolism, inflammation, and cardiovascular disease pipeline \u2013 anchored by ABP-671, a first\u2011in\u2011class URAT1 inhibitor positioned for first\u2011line gout treatment with Phase IIb\/III trials underway in China and the United States.","og_url":"https:\/\/flcube.com\/?p=61249","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-25T06:43:54+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=61249#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=61249"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Atom Therapeutics Files Hong Kong IPO \u2013 URAT1 Inhibitor ABP-671 Targets First\u2011Line Gout Treatment Market","datePublished":"2026-03-25T06:43:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=61249"},"wordCount":597,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Atom Therapeutics","IPO"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=61249#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=61249","url":"https:\/\/flcube.com\/?p=61249","name":"Atom Therapeutics Files Hong Kong IPO \u2013 URAT1 Inhibitor ABP-671 Targets First\u2011Line Gout Treatment Market - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-25T06:43:54+00:00","description":"Atom Therapeutics Co., Ltd. has submitted an initial public offering (IPO) filing to the Hong Kong Stock Exchange, seeking capital markets access to advance its metabolism, inflammation, and cardiovascular disease pipeline \u2013 anchored by ABP-671, a first\u2011in\u2011class URAT1 inhibitor positioned for first\u2011line gout treatment with Phase IIb\/III trials underway in China and the United States.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=61249#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=61249"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=61249#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Atom Therapeutics Files Hong Kong IPO \u2013 URAT1 Inhibitor ABP-671 Targets First\u2011Line Gout Treatment Market"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61249","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=61249"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61249\/revisions"}],"predecessor-version":[{"id":61252,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61249\/revisions\/61252"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=61249"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=61249"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=61249"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}